135 related articles for article (PubMed ID: 31358662)
1. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
7. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
[TBL] [Abstract][Full Text] [Related]
10. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
[TBL] [Abstract][Full Text] [Related]
11. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
12. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
13. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
14. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Chan CY; Chiu DK; Yuen VW; Law CT; Wong BP; Thu KL; Cescon DW; Soria-Bretones I; Cheu JW; Lee D; Tse AP; Zhang MS; Tan KV; Ng IO; Khong PL; Yau TC; Bray MR; Mak TW; Wong CC
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2119514119. PubMed ID: 35914158
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
16. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
17. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
[TBL] [Abstract][Full Text] [Related]
18. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
[TBL] [Abstract][Full Text] [Related]
20. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
